Epoxycyperene, also called cyperene epoxide, is a sesquiterpene oxide associated with Cyperus oils such as nagarmotha or cypriol. The live evidence base is strongest for identity and occurrence: accessible sources support its registry data, its identification in Cyperus alopecuroides by spectroscopic work, and its presence in archive-relevant nagarmotha GC-MS profiles. This pass did not verify isolated human-use pharmacology or constituent-specific toxicology, so Epoxycyperene is best framed as a chemistry marker with honest evidence gaps rather than a benefit-led constituent.
Chemical identity and composition
PubChem resolves Epoxycyperene under the title Cyperene epoxide as CID 12308850 with formula C15H24O, InChIKey ZIEAVLBEUVSHIU-UHFFFAOYSA-N, and IUPAC name 4,11,12,12-tetramethyl-5-oxatetracyclo[6.3.1.01,6.04,6]dodecane. NIST and KNApSAcK both surface CAS 25570-94-9 and the cyperene-epoxide naming. In the local archive, Bengali nagarmotha essential oil already records Epoxycyperene at 1.33%. A recent nagarmotha characterization preprint snippet lists cyperene epoxide around 2.1% to 4.1% across samples.
Aroma and practical use
- Use the recorded woody, earthy, spicy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1997 phytochemistry paper on Cyperus alopecuroides reported that epoxycyperene was identified in hydrodistillation products by spectroscopic methods and chemical conversions.
A 1997 phytochemistry paper on Cyperus alopecuroides reported that epoxycyperene was identified in hydrodistillation products by spectroscopic methods and chemical conversions.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A Bengali nagarmotha GC-MS certificate already used in the archive reported Epoxycyperene at 1.33% of the analyzed oil.
A Bengali nagarmotha GC-MS certificate already used in the archive reported Epoxycyperene at 1.33% of the analyzed oil.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2025 chemical-characterization preprint snippet for nagarmotha listed cyperene epoxide, explicitly equated with Epoxycyperene, at roughly 2.1% to 4.1% across analyzed samples.
A 2025 chemical-characterization preprint snippet for nagarmotha listed cyperene epoxide, explicitly equated with Epoxycyperene, at roughly 2.1% to 4.1% across analyzed samples.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA limit, phototoxicity warning, or controlled human safety study was verified for isolated Epoxycyperene in this research pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the accessible literature is largely identity and occurrence focused, consumer-facing copy should avoid implying established standalone tolerability or therapeutic action.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical studies or isolated therapeutic studies specific to Epoxycyperene were located in the reviewed public sources.
- No constituent-specific mechanism paper was verified beyond analytical identification and structural chemistry.
- Constituent-specific dermal sensitization, inhalation, reproductive, and chronic toxicology data were not verified in this pass.
- 2026-07-13 verification pass: web search for IFRA/RIFM dermal limit and sensitization data found no authoritative constituent-specific results; prior dermal_limit_pct (5) was an unsourced placeholder and has been corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.